Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 4:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 1,096 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Vehicle Control Clear all
Completed Phase 2 Interventional Results available

Study of SAF312 as an Eye Drop for Treatment of Eye Pain Following Photorefractive Keratectomy (PRK) Surgery

NCT02961062
View directory record Official record
Conditions
Postoperative Ocular Pain After PRK Surgery
Interventions
SAF312, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
4
States / cities
Chevy Chase, Maryland • Sioux Falls, South Dakota • Draper, Utah + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2021 · Synced Oct 19, 2026, 4:04 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of APP13007 for Treatment of Inflammation and Pain After Cataract Surgery Including a Corneal Endothelial Cell Sub-study

NCT04810962
View directory record Official record
Conditions
Ocular Inflammation and Pain After Cataract Surgery
Interventions
APP13007, 0.05%, Matching Vehicle Placebo for APP13007, 0.05%
Drug
Lead sponsor
Formosa Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
31
States / cities
Chandler, Arizona • Mesa, Arizona • Phoenix, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2023 · Synced Oct 19, 2026, 4:04 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety of PL9643 Ophthalmic Solution in Subjects With Dry Eye

NCT04268069
View directory record Official record
Conditions
Dry Eye Disease
Interventions
PL9643 Ophthalmic Solution, Placebo Ophthalmic Solution
Drug
Lead sponsor
ORA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
4
States / cities
Andover, Massachusetts • Raynham, Massachusetts • Shelby, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2020 · Synced Oct 19, 2026, 4:04 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Efficacy of a Controlled Short-term Trial of Cannabidiol (CBD) Ingestion on Reducing Symptomatic Response and Facilitating Recovery After Induced Muscle Injury

NCT04586712
View directory record Official record
Conditions
Muscle Injury, Recovery, Pain Relief
Interventions
Active CBD, Vehicle Control (Placebo)
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 35 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Oct 19, 2026, 4:04 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of Epi-on Corneal Cross-linking in Eyes With Progressive Keratoconus

NCT03442751
View directory record Official record
Conditions
Progressive Keratoconus
Interventions
Test Article A, Test Article B, Placebo, KXL medical device system
Drug · Device
Lead sponsor
Glaukos Corporation
Industry
Eligibility
12 Years to 55 Years
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Oct 19, 2026, 4:04 PM EDT
Terminated Phase 4 Interventional Results available

Safety and Efficacy of Pimecrolimus Cream 1% in Atopic Disease Modification

NCT00124709
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Pimecrolimus, Corticosteroid
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
3 Months to 18 Months
Enrollment
1,091 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
36
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2011 · Synced Oct 19, 2026, 4:04 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Role of ET-1, Physical Activity, and Sedentary Behavior in Microvascular Dysfunction Following GDM

NCT06547619
View directory record Official record
Conditions
Gestational Diabetes, Endothelial Dysfunction, Physical Inactivity
Interventions
Insulin aspart
Drug
Lead sponsor
Anna Stanhewicz, PhD
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 19, 2026, 4:04 PM EDT
Terminated Phase 3 Interventional

Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis

NCT05387707
View directory record Official record
Conditions
Pruritus, Atopic Dermatitis
Interventions
difelikefalin 0.25 mg, difelikefalin 0.5 mg, TCS Cream, Placebo, Vehicle Cream
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
61
States / cities
Scottsdale, Arizona • Fort Smith, Arkansas • Rogers, Arkansas + 56 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2024 · Synced Oct 19, 2026, 4:04 PM EDT
Recruiting Phase 2Phase 3 Interventional

A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema)

NCT07355075
View directory record Official record
Conditions
Eczema Atopic Dermatitis, Eczema, Atopic Dermatitis
Interventions
GX-03, Vehicle
Combination Product · Other
Lead sponsor
Turn Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Irving, Texas
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 19, 2026, 4:04 PM EDT
Completed Phase 2 Interventional

Study to Determine the Effects Treatment With Amlexanox 0.5% Oral Rinse Solution on Oral Mucositis Associated With Radiation Therapy for Cancer of the Head and Neck Region

NCT01083875
View directory record Official record
Conditions
Oral Mucositis
Interventions
amlexanox, Vehicle rinse
Drug
Lead sponsor
Access Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
12
States / cities
Mobile, Alabama • Little Rock, Arkansas • Bakersfield, California + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2010 · Synced Oct 19, 2026, 4:04 PM EDT
Completed Phase 2 Interventional

Clinical Study of ALLO-ASC-SHEET in Subjects with Diabetic Foot Ulcers

NCT03754465
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
ALLO-ASC-DFU, Hydrogel SHEET(Vehicle control)
Biological · Procedure
Lead sponsor
Anterogen Co., Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 23, 2025 · Synced Oct 19, 2026, 4:04 PM EDT
Terminated Phase 3 Interventional Results available

Assessment of the Safety and Efficacy Study of RGN-259 Ophthalmic Solutions for Neurotrophic Keratopathy : SEER-1

NCT02600429
View directory record Official record
Conditions
Neurotrophic Keratopathy
Interventions
RGN-259, Placebo
Drug
Lead sponsor
ReGenTree, LLC
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
11
States / cities
Lancaster, California • Colorado Springs, Colorado • Fort Collins, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2023 · Synced Oct 19, 2026, 4:04 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate CAY001 in Healthy Volunteers

NCT06845839
View directory record Official record
Conditions
Healthy
Interventions
CAY001, Placebo
Drug · Other
Lead sponsor
Cayuga Biotech, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 19, 2026, 4:04 PM EDT
Completed Phase 2 Interventional

A Phase 2 Safety and Efficacy Study of UHE-101 Cream in Subjects With Acne Vulgaris

NCT03307577
View directory record Official record
Conditions
Acne Vulgaris
Interventions
UHE-101 Cream, Vehicle Cream
Drug · Other
Lead sponsor
Therapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 24, 2019 · Synced Oct 19, 2026, 4:04 PM EDT
Terminated Phase 3 Interventional

Phase 3 Study Evaluating Efficacy and Safety of DSC127 Compared With Vehicle and With Standard-of-care in Diabetic Foot Ulcers

NCT01849965
View directory record Official record
Conditions
Diabetic Foot Ulcers
Interventions
DSC127, placebo vehicle gel, Standard of Care gel, Aquasite
Drug
Lead sponsor
Integra LifeSciences Corporation
Industry
Eligibility
18 Years and older
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
33
States / cities
Mesa, Arizona • Phoenix, Arizona • Castro Valley, California + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Oct 19, 2026, 4:04 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study to Evaluate the Efficacy and Safety of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts

NCT02971891
View directory record Official record
Conditions
Cutaneous Common Warts
Interventions
CLS006 (Furosemide) Topical Gel, Vehicle Topical Gel
Drug
Lead sponsor
Maruho Co., Ltd.
Industry
Eligibility
2 Years and older
Enrollment
484 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
30
States / cities
Mobile, Alabama • Glendale, Arizona • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2023 · Synced Oct 19, 2026, 4:04 PM EDT
Recruiting Phase 2 Interventional

Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors

NCT05639933
View directory record Official record
Conditions
Acneiform Eruption Due to Chemical, Xerosis Cutis, Paronychia
Interventions
HT-001 2% Topical Gel, HT-001 1% Topical Gel, HT-001 0.5% Topical Gel, HT-001 Placebo
Drug
Lead sponsor
Hoth Therapeutics, Inc.
Other
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
9
States / cities
Irvine, California • Orange, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 19, 2026, 4:04 PM EDT
Completed Phase 3 Interventional Results available

A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations

NCT00942604
View directory record Official record
Conditions
Actinic Keratoses
Interventions
PEP005 (ingenol mebutate) Gel, Vehicle gel
Drug
Lead sponsor
Peplin
Industry
Eligibility
18 Years and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
17
States / cities
Hot Springs, Arizona • San Diego, California • Alpharetta, Georgia + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 19, 2026, 4:04 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study Evaluating the Efficacy and Safety of OCS-01 Eyedrops Compared to Vehicle for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery

NCT05147233
View directory record Official record
Conditions
Inflammation Eye Pain, Postoperative Cataract
Interventions
OCS-01, Vehicle
Drug
Lead sponsor
Oculis
Industry
Eligibility
18 Years and older
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
25
States / cities
Chandler, Arizona • Phoenix, Arizona • Fayetteville, Arkansas + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2025 · Synced Oct 19, 2026, 4:04 PM EDT
Completed Phase 3 Interventional Results available

Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatment of Acne Vulgaris

NCT04214639
View directory record Official record
Conditions
Acne Vulgaris
Interventions
IDP-126 Gel, IDP-126 Vehicle Gel
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
9 Years and older
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
11
States / cities
Bryant, Arkansas • Fremont, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2024 · Synced Oct 19, 2026, 4:04 PM EDT
Not listed Phase 3 Interventional

Study of EBI-005 in Dry Eye Disease (DED)

NCT02405039
View directory record Official record
Conditions
Dry Eye
Interventions
EBI-005, Placebo
Drug
Lead sponsor
Eleven Biotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
12
States / cities
Birmingham, Alabama • Newport Beach, California • Hamden, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2015 · Synced Oct 19, 2026, 4:04 PM EDT
Active, not recruiting Phase 3 Interventional

Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)

NCT06958211
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Ruxolitinib Cream, Vehicle Cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years and older
Enrollment
573 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
67
States / cities
Birmingham, Alabama • Montgomery, Alabama • Phoenix, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 19, 2026, 4:04 PM EDT
Completed Phase 1 Interventional Results available

A Study to Evaluate and Compare the Efficacy and Pharmacokinetics of MK-0873 for the Treatment of Plaque Psoriasis (MK-0873-022)

NCT01235728
View directory record Official record
Conditions
Psoriasis, Plaque Psoriasis
Interventions
MK-0873 2% Cream, MK-0873 vehicle (placebo) Cream, Calcitriol Cream
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Fort Myers, Florida • Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Feb 8, 2019 · Synced Oct 19, 2026, 4:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics and Pharmacodynamics of Long Acting Human Growth Hormone (hGH) Product (MOD-4023) in Healthy Caucasian and Japanese Volunteers

NCT02418767
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
MOD-4023, Placebo
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Sep 30, 2019 · Synced Oct 19, 2026, 4:04 PM EDT